REVB
Revelation Biosciences, Inc.
$0.96
-5.88%
2026-05-08
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Key Fundamentals
P/E Ratio
0.00
Forward P/E
-0.30
EPS (TTM)
$-23.95
ROE
-131.4%
Profit Margin
0.0%
Debt/Equity
8.43
Price/Book
0.18
Beta
-0.14
Market Cap
$3.7M
Avg Volume (10D)
47K
Recent Breakout Signals
No recent breakout signals detected for REVB.
Recent Price Range (60 Days)
60D High
$1.57
60D Low
$0.95
Avg Volume
86K
Latest Close
$0.96
Get breakout alerts for REVB
Sign up for Breakout Scanner to receive daily notifications when REVB triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Revelation Biosciences, Inc. (REVB) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors REVB daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. REVB operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.